We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |


Richard D. deShazo, MD; John E. Salvaggio, MD
JAMA. 1984;252(16):2198-2201. doi:10.1001/jama.1984.03350160066020.
Text Size: A A A
Published online


The past two years have been especially notable in that techniques first developed for basic research into mechanisms of host defense continue to be rapidly applied to investigation of human disease. This new applied methodology provides useful information about disease pathogenesis and new ideas for disease treatment. Although present regulation of the immune system at the clinical-therapeutic level continues to focus on "down-regulation" of apparent "hypersensitivity" with corticosteroids, cytotoxic agents, and the new T-lymphocyte suppressing agent, cyclosporine, attempts at augmentation of immune responses with new families of so-called biologic-response modifiers have now been initiated. This development has occurred as a result of the newly acquired capability to isolate, characterize, and produce the quantities of these compounds necessary for controlled clinical trials. Thus, potent immunoregulatory compounds, like interleukins and interferons, so far the most carefully investigated biologic-response modifiers, can be identified and mass-produced in cloned tumor cells or in bacteria functioning


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.